{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+Interferon+Alfa+2a", "query": { "intervention": "Pegylated Interferon Alfa 2a" }, "page_size": 10 }, "pagination": { "page": 1, "page_size": 10, "total_count": 202, "total_pages": 21, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Pegylated+Interferon+Alfa+2a&page=2&page_size=10", "previous_page_url": null }, "source": "remote", "last_synced_at": "2026-09-30T10:16:59.044Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT00078403", "title": "Pegylated Interferon Alfa-2a Maintenance Therapy and Liver Disease Progression in People Infected With Both HIV and Hepatitis C Virus (HCV)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "HIV Infections", "Hepatitis C", "Liver Disease" ], "interventions": [ { "name": "Peginterferon alfa-2a", "type": "DRUG" }, { "name": "Ribavirin", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "National Institute of Allergy and Infectious Diseases (NIAID)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 333, "start_date": "2004-07", "completion_date": "2009-02", "has_results": true, "last_update_posted_date": "2021-11-08", "last_synced_at": "2026-09-30T10:16:59.044Z", "location_count": 36, "location_summary": "Birmingham, Alabama • Los Angeles, California • Palo Alto, California + 23 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" }, { "city": "San Diego", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00078403" }, { "nct_id": "NCT00545233", "title": "A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) Plus COPEGUS (Ribavirin) With or Without Pioglitazone in Treatment-Naive Patients With Chronic Hepatitis C and Insulin Resistance.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "peginterferon alfa-2a [Pegasys]", "type": "DRUG" }, { "name": "ribavirin [Copegus]", "type": "DRUG" }, { "name": "Pioglitazone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 155, "start_date": "2008-01", "completion_date": "2010-12", "has_results": true, "last_update_posted_date": "2012-05-07", "last_synced_at": "2026-09-30T10:16:59.044Z", "location_count": 65, "location_summary": "Birmingham, Alabama • Tucson, Arizona • Anaheim, California + 53 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fresno", "state": "California" }, { "city": "La Jolla", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00545233" }, { "nct_id": "NCT07623200", "title": "A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Essential Thrombocythemia" ], "interventions": [ { "name": "INCA033989", "type": "DRUG" }, { "name": "Best Available Treatment", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Incyte Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 426, "start_date": "2026-09-08", "completion_date": "2030-11-01", "has_results": false, "last_update_posted_date": "2026-09-14", "last_synced_at": "2026-09-30T10:16:59.044Z", "location_count": 40, "location_summary": "Gilbert, Arizona • Duarte, California • Greenbrae, California + 32 more", "locations": [ { "city": "Gilbert", "state": "Arizona" }, { "city": "Duarte", "state": "California" }, { "city": "Greenbrae", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Palo Alto", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07623200" }, { "nct_id": "NCT00720434", "title": "A Dose Ranging Study Of PF-00868554 In Combination With PEGASYS And COPEGUS In Patients With Chronic Hepatitis C Genotype 1 Infection", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "PF-00868554", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Pfizer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 35, "start_date": "2008-08", "completion_date": "2010-03", "has_results": true, "last_update_posted_date": "2013-08-26", "last_synced_at": "2026-09-30T10:16:59.044Z", "location_count": 9, "location_summary": "La Jolla, California • San Francisco, California • Orlando, Florida + 5 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Orlando", "state": "Florida" }, { "city": "Springfield", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00720434" }, { "nct_id": "NCT00107653", "title": "Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1.", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE4" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Ribavirin", "type": "DRUG" }, { "name": "Peginterferon alfa-2a", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 569, "start_date": "2004-10", "completion_date": "2007-09", "has_results": true, "last_update_posted_date": "2016-06-21", "last_synced_at": "2026-09-30T10:16:59.044Z", "location_count": 58, "location_summary": "Scottsdale, Arizona • Tucson, Arizona • Anaheim, California + 46 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Fountain Valley", "state": "California" }, { "city": "Fresno", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00107653" }, { "nct_id": "NCT06072612", "title": "Study of the Bria-IMT Regimen and CPI vs Physicians' Choice in Advanced Metastatic Breast Cancer.", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Breast Cancer", "Metastatic Breast Cancer", "Breast Neoplasm", "Breast Cancer Metastatic", "End Stage Cancer" ], "interventions": [ { "name": "SV-BR-1-GM", "type": "BIOLOGICAL" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Interferon infiltration of the inoculation site", "type": "DRUG" }, { "name": "Retifanlimab", "type": "DRUG" }, { "name": "Treatment of Physician's Choice", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "BriaCell Therapeutics Corporation", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 404, "start_date": "2023-12-05", "completion_date": "2028-06", "has_results": false, "last_update_posted_date": "2026-09-02", "last_synced_at": "2026-09-30T10:16:59.044Z", "location_count": 79, "location_summary": "Phoenix, Arizona • Tucson, Arizona • Anaheim, California + 60 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "Tucson", "state": "Arizona" }, { "city": "Anaheim", "state": "California" }, { "city": "Bakersfield", "state": "California" }, { "city": "Beverly Hills", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT06072612" }, { "nct_id": "NCT00984620", "title": "Short Term Treatment With BI 201335, Peginterferon-alpha 2a and Ribavirin in Hepatitis c Virus Genotype-1 Treatment-naïve Patients (SILEN-C3)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C" ], "interventions": [ { "name": "BI 201335", "type": "DRUG" }, { "name": "Pegylated Interferon-alpha (IFN)", "type": "DRUG" }, { "name": "Ribavirin (RBV)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Boehringer Ingelheim", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "70 Years", "sex": "ALL", "summary": "18 Years to 70 Years" }, "enrollment_count": 160, "start_date": "2009-09", "completion_date": null, "has_results": true, "last_update_posted_date": "2015-09-07", "last_synced_at": "2026-09-30T10:16:59.044Z", "location_count": 6, "location_summary": "Tulepo, Mississippi • New York, New York • Germantown, Tennessee + 3 more", "locations": [ { "city": "Tulepo", "state": "Mississippi" }, { "city": "New York", "state": "New York" }, { "city": "Germantown", "state": "Tennessee" }, { "city": "Jackson", "state": "Tennessee" }, { "city": "Nashville", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT00984620" }, { "nct_id": "NCT02407080", "title": "Open Label Study of Single Agent Oral RG7388 in Patients With Polycythemia Vera and Essential Thrombocythemia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Polycythemia Vera", "Essential Thrombocythemia" ], "interventions": [ { "name": "RG7388", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "John Mascarenhas", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 13, "start_date": "2015-04", "completion_date": "2018-12-19", "has_results": false, "last_update_posted_date": "2019-09-12", "last_synced_at": "2026-09-30T10:16:59.044Z", "location_count": 3, "location_summary": "Washington D.C., District of Columbia • New York, New York • Winston-Salem, North Carolina", "locations": [ { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "New York", "state": "New York" }, { "city": "Winston-Salem", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT02407080" }, { "nct_id": "NCT01482403", "title": "A Study of Mericitabine in Combination With Boceprevir and Pegasys/Copegus in Patients With Chronic Hepatitis C", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "boceprevir", "type": "DRUG" }, { "name": "mericitabine", "type": "DRUG" }, { "name": "mericitabine placebo", "type": "DRUG" }, { "name": "boceprevir placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 58, "start_date": "2011-11", "completion_date": "2014-01", "has_results": false, "last_update_posted_date": "2016-08-05", "last_synced_at": "2026-09-30T10:16:59.044Z", "location_count": 7, "location_summary": "Littleton, Colorado • Chicago, Illinois • Shreveport, Louisiana + 4 more", "locations": [ { "city": "Littleton", "state": "Colorado" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Shreveport", "state": "Louisiana" }, { "city": "Detroit", "state": "Michigan" }, { "city": "Kansas City", "state": "Missouri" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482403" }, { "nct_id": "NCT00869661", "title": "A Study of RO5024048 in Combination With Pegasys and Copegus in Treatment-Naive Patients With Chronic Hepatitis C, Genotype 1 or 4", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Hepatitis C, Chronic" ], "interventions": [ { "name": "Copegus", "type": "DRUG" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "RO5024048", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hoffmann-La Roche", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "ALL", "summary": "18 Years to 65 Years" }, "enrollment_count": 413, "start_date": "2001-02", "completion_date": "2012-02", "has_results": false, "last_update_posted_date": "2016-11-02", "last_synced_at": "2026-09-30T10:16:59.044Z", "location_count": 21, "location_summary": "Birmingham, Alabama • La Jolla, California • Sacramento, California + 18 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "La Jolla", "state": "California" }, { "city": "Sacramento", "state": "California" }, { "city": "San Diego", "state": "California" }, { "city": "San Francisco", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT00869661" } ] }